LIFECORE BIOMEDICAL, INC. \DE\ 8-K

What Happened
Lifecore Biomedical, Inc. announced its consolidated financial results for the quarter ended March 31, 2026 by issuing a press release on May 6, 2026. The press release reporting the company’s quarterly results is furnished as Exhibit 99.1 to the Form 8-K. On the same day the company made an investor presentation available on its website, furnished as Exhibit 99.2, in compliance with Regulation FD.

Key Details

• Date of filing and disclosures: May 6, 2026.
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Press release containing the consolidated financial results: Exhibit 99.1 to the 8-K.
• Investor presentation posted under Regulation FD and furnished as Exhibit 99.2.
• Form 8-K signed by Ryan D. Lake, Chief Financial Officer.

Why It Matters
This 8-K signals that Lifecore has publicly released its Q1 2026 quarterly results and updated investors with an accompanying presentation—materials investors should review for revenue, earnings, margins, and any operational or guidance commentary. The Regulation FD posting means the company aimed to make the presentation broadly available to all investors at the same time. The 8-K itself references those materials; investors should read Exhibit 99.1 (press release) and Exhibit 99.2 (presentation) or visit the company website for the detailed financial metrics and management commentary.